Bank of America Merrill Lynch is out with its report today on Davita DVA, raising its PO from $96 to $102.
In its report, Bank of America Merrill Lynch writes, "We continue to like the long-term outlook for DVA given our belief in its strong organic growth and good FCF generation. We are raising our 2011/12/13 ests (which do not include DSI) to $4.79/$5.68/$6.27 from $4.62/$5.10/$5.64 and raising our PO to $102 from $96."
Bank of America Merrill Lynch maintains Buy on DVA.
At the time of posting, shares of DVA were trading pre-market at $81.00, up 3.28% from Wednesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBank of America Merrill LynchHealth CareHealth Care Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in